|
|
|
 |
FDA Approval Activities for this Drug…
Famvir (famciclovir) Tablets, Novartis NDA 20-363/SLR-019 3/27/01 5/1/01 Famvir (famciclovir) Tablets, 125mg, 250mg, & 500mg SmithKline Beecham NDA 20-363/S-010/S-014/S-016 6/12/98 1/6/99 | Famvir Indication: for the treatment of recurrent mucocutaneous herpes simplex infections in HIV-infected patients. | Famvir (famciclovir) Tablets Novartis NDA 20-363/SLR-019 | Famvir (famciclovir) Tablets, Novartis Pharma, Labeling Revision | Famvir (famciclovir) tablets, Novartis Pharma, New Dosage Regimen & New or Modified Indication | Famciclovir Tablets, Teva Pharma, Tentative Approval | Famciclovir Tablets, Teva Pharma, Approval | Famvir (famciclovir) Tablets, Novartis Pharmaceuticals Corporation, Labeling Revision | Famciclovir Tablets, Roxane Laboratories, Inc., Tentative Approval | Famvir (famciclovir) Tablets, Novartis Pharmaceuticals Corp., Efficacy Supplement with Clinical Data to Support | Famciclovir Tablets, Watson Laboratories, Inc., Approval | Famciclovir Tablets, Watson Laboratories, Inc., Tentative Approval | Famvir (famciclovir) Tablets, Novartis Pharmaceuticals Corp., Efficacy Supplement with Clinical Data to Support | Famciclovir Tablets, Aurobindo Pharma Limited, Tentative Approval | Famciclovir Tablets, Mylan Pharmaceuticals, Inc., Approval | Famciclovir Tablets, Watson Laboratories, Inc., Approval | Famciclovir Tablets, Roxane Laboratories, Inc., Approval | Famciclovir Tablets, Aurobindo Pharma Ltd., Approval | Famciclovir Tablets, Apotex Inc., Approval
  
|